UNAIDS director calls for ARV production in Africa

"Executive Director of UNAIDS Michel Sidibe Wednesday called for the production of anti-retroviral drugs [ARVs] in Africa to make the life-saving medicines against AIDS accessible to patients and boost the medicines manufacturing sector on the continent," PANA/AfriqueJet reports. Speaking at the 16th West African Economic and Monetary Union (UEMOA) Summit in Lome, Togo, "Sidibe said it was time for the continent to negotiate strong partnerships with emerging countries, including India and Brazil, to support the local production of ARVs in Africa," the news service writes, adding, "According to [Sidibe], Africa accounts for only one percent of the medicine manufacturing sector that is expected to generate as much as $1 trillion by 2015" (6/7).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    Study finds potential for antidiabetic drugs to modify osteoarthritis risk